A practical guide to combination advanced therapy in inflammatory bowel disease

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Inflammatory bowel disease (IBD) presents challenges with current treatments, as many patients experience non-response or loss of response over time.
• Advanced targeted immunomodulator (TIM) monotherapy may not be sufficient for all IBD patients, necessitating exploration of alternative strategies.

Purpose of the Study:

• To review the existing literature on advanced combination therapy (ACT) for inflammatory bowel disease (IBD).
• To provide practical guidance for implementing ACT in clinical settings for difficult-to-treat IBD populations.

Main Methods:

• Literature review of observational and controlled studies on ACT in IBD.
• Analysis of evidence supporting the efficacy and safety of ACT compared to monotherapy.

Main Results:

• Evidence suggests potential benefits of ACT in specific IBD patient groups compared to advanced targeted immunomodulator (TIM) monotherapy.
• Additional data is required to refine combination TIM strategies and assess long-term risks.

Conclusions:

• ACT demonstrates potential benefits for both Crohn's disease and ulcerative colitis, though its use is currently off-label.
• Long-term controlled data is essential; successful ACT implementation requires individualized patient assessment and close monitoring.